Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183016 | 0.92 | MCL1 (0.33) | MCL1MEN1KMT2A | |
| SCHEMBL3456299 | 0.90 | CYP2C19 (0.35) | MCL1MEN1KMT2AHTT | |
| SCHEMBL20524331 | 0.77 | — | — | |
| SCHEMBL28549876 | 0.72 | CYP2C19 (0.47) | MEN1KMT2AHTT | |
| SCHEMBL26683181 | 0.72 | CYP4F2 (0.42) | — | |
| SCHEMBL4143787 | 0.72 | — | — | |
| SCHEMBL798476 | 0.72 | CYP4F2 (0.42) | — | |
| SCHEMBL4201007 | 0.70 | — | — | |
| SCHEMBL7134820 | 0.70 | L3MBTL1 (0.32) | KMT2A | |
| SCHEMBL6137242 | 0.70 | MCL1 (0.36) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | claimed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | claimed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | claimed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | claimed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | claimed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | claimed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1303485-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | MCL1 321/4885MEN1 769/4885KMT2A 2194/4885 |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | TBXA2R, CYP11B2, NR1I2 | MCL1 1282/4885MEN1 1270/4885KMT2A 3178/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | MCL1 3759/4885MEN1 3712/4885KMT2A 2346/4885 |
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | MCL1 3453/4885MEN1 2985/4885KMT2A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.